Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III/IV after hematopoietic stem cell transplantation

Full text
Author(s):
Show less -
Dotoli, G. M. ; De Santis, G. C. ; Orellana, M. D. ; de Lima Prata, K. ; Caruso, S. R. ; Fernandes, T. R. ; Rensi Colturato, V. A. ; Kondo, A. T. ; Hamerschlak, N. ; Simoes, B. P. ; Covas, D. T.
Total Authors: 11
Document type: Journal article
Source: BONE MARROW TRANSPLANTATION; v. 52, n. 6, p. 859-862, JUN 2017.
Web of Science Citations: 24
Abstract

Acute GvHD (aGvHD) is a life-threatening complication of hematopoietic stem cell transplantation. Frontline therapy for aGvHD consists of corticosteroid administration. However, similar to 25% of the patients have a steroid-refractory disease, a sign of poor prognosis. An alternative therapy for steroid-refractory aGvHD is infusion of mesenchymal stromal cells (MSCs). Herein, we report the results of 46 patients treated with MSC infusion as salvage therapy for steroid-refractory aGvHD III/IV (78% grade IV). Patients received a median cumulative dose of MSCs of 6.81 x 10(6)/kg (range, 0.98-29.78 x 10(6)/kg) in a median of 3 infusions (range, 1-7). Median time between the onset of aGvHD and the first MSC infusion was 25.5 days (range, 6-153). Of the patients, 50% (23/46) presented clinical improvement. Of these, 3 patients (13%) had complete response, 14 (61%) had partial response and 6 (26%) had transient partial response. The estimated probability of survival at 2s year was 17.4%. Only 2 patients (4.3%) presented acute transient side effects (nausea/vomiting and blurred vision) during cell infusion. No patient had late or severe side effects because of MSC infusion. These results suggest that this therapeutic modality is safe and should be considered for steroid-refractory aGvHD, especially in countries where other second-line agents are less available. (AU)

FAPESP's process: 13/08135-2 - CTC - Center for Cell-Based Therapy
Grantee:Dimas Tadeu Covas
Support Opportunities: Research Grants - Research, Innovation and Dissemination Centers - RIDC